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Abstract: Mitochondria and mitochondrial DNA have important roles to play in development.
In primordial germ cells, they progress from small numbers to populate the maturing oocyte with
high numbers to support post-fertilization events. These processes take place under the control of
significant changes in DNA methylation and other epigenetic modifiers, as well as changes to the DNA
methylation status of the nuclear-encoded mitochondrial DNA replication factors. Consequently,
the differentiating germ cell requires significant synchrony between the two genomes in order to
ensure that they are fit for purpose. In this review, I examine these processes in the context of female
germline stem cells that are isolated from the ovary and those derived from embryonic stem cells and
reprogrammed somatic cells. Although our knowledge is limited in this respect, I provide predictions
based on other cellular systems of what is expected and provide insight into how these cells could be
used in clinical medicine.
Keywords: mitochondria; mitochondrial DNA; mitochondrial DNA copy number; female germ cells;
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1. Introduction
There is an increasing interest in the generation and use of female germline stem cells to study their
properties and propensity to produce mature oocytes [1]; and to use them to treat infertile couples [2–4].
Consequently, there is a need to understand the roles that mitochondria and the mitochondrial genome
play in development; and to further understand how the failure to establish synchrony between the
nuclear and mitochondrial genomes could render these cells dysfunctional. In this review, I describe
the processes that would affect female germline stem cells, whether isolated from the ovary, or derived
from embryonic stem cells or induced pluripotent stem cells, and how their failure to act affects gamete
quality and fertilization outcomes. Importantly, I demonstrate that the interactions of the nuclear
and mitochondrial genomes are complex and appear to require their establishment from the very
early stages of development to ensure that there would be no inherent complications passed onto the
resultant offspring.
2. The Role of Mitochondria
Mitochondria play critical roles in cellular function and are found in nearly all mammalian cells.
In adult cells, mitochondria tend to be mature, as they form highly structured networks that influence
cellular function. They have the capability to store Ca2+ [5], as well as initiate other key biological
processes such as steroidogenesis through the reduction of cholesterol [6]. They further act by balancing
free radical activity to reduce excess free radicals that are not required for intracellular activities, and
would, otherwise, affect cellular function [7]. They are regulators of apoptosis and necrosis [8], as
well as innate immune responses to pathogens and cell stress [9–11]. Of increasing importance is
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their role as activators and regulators of the epigenome. In this instance, the by-products of the citric
acid cycle, for example, α-Ketoglutarate, act as co-factors with the TET family of proteins to mediate
the transition of 5-methylcytosine to 5-hydroxymethylcytosine, i.e., to convert methylated DNA to
demethylated DNA [12]. Likewise, they can modulate the activity of histone modifiers [13]. Finally,
they act as the vehicles for the propagation and transmission of the mitochondrial genome through
the developing female organism and into subsequent generations [14] to maintain and ensure the
maternal-only transmission of mtDNA.
In embryonic stem cells, adult stem cells, primordial germ cells, egg precursor cells, and maturing
oocytes and embryos, mitochondria are naïve, transparent, roundish-oval-like structures, which have
limited capacity to produce energy [15,16]. This is unlike their mature counterparts that are elongated,
dense structures, which form complex networks to promote interactions between mitochondria [17].
Early, naïve cells also have few mitochondria and they achieve these complex networks by multiplying
and, simultaneously, migrating from one end of the cell to surround the nucleus and populate the
other end of the cell as they undergo differentiation into mature cell types [18]. They also initiate
mitochondrial fusion through the expression of the Mitofusins (Mfn1 and 2) that promote the state of a
mature mitochondrial continuum within a cell [19].
3. Energy Production
There are several energy generating pathways in the cell (see Figure 1). One key pathway is
glycolysis, which takes place in the cell’s cytoplasm [20]. It produces relatively low levels of ATP
(4 mol for every 2 mol of glucose invested in the process) but is a highly efficient and rapid process and
is favored by fast replicating cells that require energy quickly [20]. In mammalian systems, they would
include cells that do not perform complex functions such as embryonic cells, embryonic stem cells,
adult stem cells, tumor-initiating cells, and female germ cells from various stages of development up
to and including mature oocytes. Blood cells also rely on glycolysis as they are recruited in a rapid
fashion to react to an insult [21].
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cell, glycolysis generates four molecules of ATP for every two molec les of glucose invested. This is
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Cells that have more complex functions, for example heart, muscle, and nerve cells, use the
by-products of glycolysis that pass into the mitochondria [22,23] (Figure 1). Pathways that include
β-oxidation and the citric acid cycle provide electrons that enter the electron transfer chain to produce
the vast majority of cellular ATP, approximately 36 mol from 2 mol of glucose invested, through the
biochemical process of oxidative phosphorylation (OXPHOS) (Figure 1) [20]. The electron transfer
chain is located in the inner mitochondrial membrane and also establishes the mitochondrial membrane
potential that provides the mitochondrion with a barrier to regulate the import and export of factors
and protect its integrity and the viability of the cell [5,15]. In cells of a more complex nature, the folding
of the inner membrane results in cristae that provide a denser, more opaque nature and is indicative of
their higher capacity for OXPHOS [24]. Unlike any other cellular apparatus in the cell, the electron
transfer chain is encoded by two separate genomes: the nuclear and the mitochondrial genomes.
4. The Mitochondrial Genome
The mammalian mitochondrial genome ranges from 16.2kb (mouse) [25] to 16.7kb (pig) [26] in
size. It encodes 13 of the approximate 100 subunits of the electron transfer chain, 22 tRNAs and
2 rRNAs. It has one major non-coding region, the Displacement or D-loop, which comprises two
hypervariable regions indicative of an individual’s maternal ancestry; and the control region, which
contains regulatory sites for the initiation of transcription and replication. The control region is also
the site of interaction for the nuclear-encoded transcription and replication factors that translocate to
the mitochondrion to drive these events. mtDNA copy number is cell type specific and relates to the
ATP requirements of that particular cell for OXPHOS-derived ATP [23].
5. The Regulation of mtDNA Copy Number during Development
mtDNA copy number is strictly regulated during development. The primordial germ cells, the
very first germ cells to be laid down following migration into the ovary [27,28], have very low levels
of mtDNA, approximately 200 copies per cell [29–31]. These copies then form the template for all
mtDNA that is transmitted through the germline; and, during oogenesis, are exponentially replicated
(Figure 2) [29,30,32]. As mitochondria maintain their immature status during oogenesis, they do not
contribute extensively to the generation of ATP. Consequently, the naivety of these mitochondria and
the high mtDNA copy number present in the mature, metaphase II oocyte, is regarded as an investment
in subsequent developmental events as, just prior to this stage, the last mtDNA replication event takes
place until post-gastrulation in the embryo proper [33]. This counters the argument that mitochondria
have a key role to play in ‘fueling oocyte activity’ [34] and supports the view that mitochondria in very
early development maintain cell viability by having efficient membrane potentials generated by protons
passing from the electron transfer chain into the mitochondrial inner membrane space [35,36]; and that
loss of OXPHOS does not prevent germ cell differentiation [37]. Consequently, oocyte mitochondria
act as vehicles for the transmission of the mitochondrial genome. Between the germinal vesicle and
the mature metaphase II stages, there are a number of refining mtDNA replication events that likely
act as purifying processes prior to the metaphase II stage, which contains the mtDNA available for
transmission through to the offspring [38].
During preimplantation development, as there is no replication of mtDNA, when each cell divides
the mtDNA content of each newly formed embryonic cell is considerably reduced [38] (Figure 2). Indeed,
there appears to be an active process to extrude mtDNA from the embryo during preimplantation
development, as mtDNA from the embryo is found in its neighbouring environment [39]. The blastocyst,
which represents the first differentiation and compartmentalisation events in the embryo, mediated
by lineage specific gene expression [40] and metabolic changes [41], initiates mtDNA replication in
the trophectodermal cells [38]. On the other hand, the cells of the inner cell mass continue to dilute
out their mtDNA content as they divide [38] and, just prior to gastrulation, establish the ‘mtDNA set
point’ [42–44].
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Figure 2. The regulation of mtDNA copy number during development. In primordial germ cells,
mtDNA is maintained at low levels. As oogenesis progresses, mtDNA copy number increases
significantly and is then arrested at the metaphase II stage. A threshold (broken blue line) needs to
be reached in order that oocytes mature and fertilize. Following fertilization, mtDNA copy number
decreases through to the blastocyst stage. mtDNA replication is initiated in the trophectoderm,
whilst the ICM continues to reduce mtDNA copy number. This enables the developing embryo to
establish the mtDNA set point prior to differentiation. Following commitment to a specific lineage,
cells then replicate their mtDNA in a cell-specific manner to enable them to perform their specialized
functions through OXPHOS, as required. Furthermore, there are synchronous changes to DNA
methylation and gene expression profiles throughout these processes. TET enzymes reduce parental
DNA methylation through to the blastocyst stage whilst de novo DNA methylation, mediated by
DNMT3a and DNMT3b, is initiated in the blastocyst. DNMT1 then maintains the newly established
cell-specific DNA methylation profiles.
The mtDNA set point contains the founder population of mtDNA that contributes to the primordial
germ cells of the next generation and to the somatic tissues of the offspring (Figure 2). The mtDNA set
point contains very few copies of mtDNA per cell (< 100 copies). This template not only contributes
to the primordial germ cells of the next generation but also restricts the units of mtDNA inheritance
to approximately 200 copies through a recycling process that exists to maintain the strict maternal
inh ritance of mtDNA and d fin s the molecules of mtDNA contributing to an individual’s maternal
ances ral lineage. Indeed, this might be a defining stage i development that could account for the
inclusion or rejection of sperm mtDNA that has bypassed the t ght elimination process [45–47], wh ch
takes places prior to embryonic genome activation [48], although this form of biparental transmission
tends to be a very rare event [45]. Furthermore, this templ e is used by the somatic tiss and is
replicated in a c ll sp cific man r so that cells giving rise to complex functions such as heart, muscle,
and brain cells acquire the high numbers of mtDNA copy they require to perform their complex
fun tions and those that primarily rely on glycolysis acquire c siderably fewer copies (Figure 2).
6. mtDNA Replication Events Are under th Contr l of the Nuclear Genome
One of the key attributes to mtDNA replication is that the process is under the control of a number
of genes encoded by the nuclear genome, which combine with the mitochondrial genome to form
nucleoids [49,50]. Indeed, this complex process is tightly coupled to mitochondrial biogenesis
in that a number of these factors appear to be precursors or upstream regulators of mtDNA
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replication [51]. These include STAT3, HIF1α, SIRT1, MYC, PGC1α/β, NRF1/2, ERRα/β/γ, SIRT3,
and PPARα/β. However, the key interactors with the mitochondrial genome are the mitochondrial
single-stranded-binding protein (mtSSB); the mitochondrial-specific helicase Twinkle, the catalytic
subunit of the mitochondrial-specific polymerase (POLGA) and its accessory subunit (POLGB); and
mitochondrial-specific DNA topoisomerase I (TOP1MT) [49,51]. Not only does there need to be a high
degree of compatibility between the two genomes to ensure that the subunits of the electron transport
chain function effectively together, but also the presence and persistence of mtDNA in the germline
is reliant on the nuclear genome being able to transcribe and replicate the mitochondrial genome,
especially during germ cell differentiation as mtDNA copy number increases considerably. Both facets
are important to cellular function.
7. The Relationship between DNA Methylation, mtDNA Replication and Oogenesis
Oogenesis is under the control of DNA methylation [52,53]. The later stages of oogenesis
are associated with the reduction in DNA methylation [52,53] and consistent with increases in
mtDNA copy number [29,30] (Figure 2). Consequently, it appears that the early female germ
cells are initially extensively DNA methylated and then undergo epigenetic reprogramming
with demethylation-resistant regions being enriched for repressive chromatin marks, for example
H3K9me2/3, and regions that demethylate being enriched for active chromatin marks, namely H3K4me3
or H3K27ac [54]. They also exhibit low mtDNA copy numbers [29–31]. Indeed, this is not dissimilar to
the patterns of DNA methylation [55] and mtDNA copy number in naïve, pluripotent, embryonic stem
cells [56–58] and the changes in DNA methylation that take place as these cells differentiate into mature
cell types [59], although it appears that DNA methyation is regulated in a very different manner by the
two key processes (the TET and DNMT pathways) [12,58,60]. Importantly, it remains to be determined
whether these synchronous changes in mtDNA replication and DNA methylation are interlinked or
merely concurrent.
Whilst it has already been argued that there is no active replication taking place which leads to
persistent increases in mtDNA copy number prior to gastrulation, it is evident from studies in embryonic
stem cells that there are a number of large-scale but short-lived replication events. These events act as
checking mechanisms prior to differentiation to ensure that the nuclear and mitochondrial genomes
are effectively interacting, and low levels of mtDNA copy number are then restored [61,62]. One key
mtDNA replication event takes place on day six of differentiation in mouse embryonic stem cells [61],
equivalent to embryonic day six (E7.5). This is consistent with embryonic lethality observed at E7.5 in
mouse embryos that are homozygous null for the catalytic subunit of the mtDNA specific polymerase
(Polg) [63]. Indeed, failure to replicate mtDNA at this critical time point prevents embryonic stem cells
from completing differentiation and is indicative of somatic cells that have been reprogrammed to
be embryonic stem-like cells, namely induced pluripotent stem (iPS) cells, that have not undergone
complete reprogramming [62]. However, when such cells are treated with DNA demethylation agents,
they then have the capability to mediate key stage-specific mtDNA replication events, especially at day
6, and are then able to complete differentiation into mature cell types.
A similar scenario exists in tumor initiating cells in that they do not have the capability to complete
differentiation. To this extent, tumor initiating cells initiate the process of differentiation but, due to their
extensive hyper-methylation, they are unable to synchronize differentiation with synchronous increases
in mtDNA copy number [64]. As a result, they are caught in a ‘mtDNA trap’ where differentiation and
mtDNA replication stall [65]. These cells, thus, rely on aerobic glycolysis and proliferate extensively
to propagate tumor formation [66]. However, as with incompletely reprogrammed iPS cells, the use
of DNA demethylation agents enables tumor initiating cells to complete differentiation and replicate
their mtDNA in a manner synchronous with differentiation [67,68].
In relation to mtDNA replication, the mtDNA replication factors are known to be under the
control of DNA methylation and in a cell-specific manner that accounts for cell-specific mtDNA
copy number [57,68]. Indeed, whilst the majority of factors appear to be DNA methyated to varying
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degrees, only POLGA and TOP1MT are significantly altered following the use of DNA demethylation
agents [57,68]. Furthermore, methylation at exon 2 of POLGA has been shown to be regulated during
embryonic stem cell differentiation [57,67] and in the final stages of oocyte maturation [69] and, thus,
is also likely during germ cell differentiation.
8. The Importance of mtDNA Replication Efficiency in Differentiating Female Germline Stem Cells
Female germline stem cells can be derived through a number of processes [28]. The population
that is present in the ovary, mainly primordial germ cells, are known to mature during oogenesis.
However, not all of these will give rise to primordial follicles as many will be eliminated through
atresia prior to birth [70] and these outcomes are not related to OXPHOS even though significant
increases in mtDNA copy take place [71]. Furthermore, not all follicles are recruited to become the
dominant follicle that gives rise to singleton pregnancies. In a number of instances, the oocytes of
some women attending assisted reproductive clinics exhibit reduced mtDNA copy number in their
metaphase II oocytes [72–74]. This most likely relates to the failure of the differentiating oocyte to
regulate the replication of mtDNA during oogenesis [69].
Female germline stem cells derived from the ovary of a number of adult species [1,3,75,76], for
example egg precursor cells or oogonial stem cells, exhibit many properties similar to adult stem cells
in that they express markers associated with early progenitor cells, self-renewal and proliferation and
regulators of the cell cycle [1,76,77], although their presence is still deemed to be controversial [78].
Whilst the properties can be species specific, for example the contrast between mouse and pig egg
precursor cells [76,77], they exhibit similar differences observed between mouse and human embryonic
stem cells where mouse embryonic stem cells demonstrate a more pluripotent, naïver state [79].
Furthermore, egg precursor cells exhibit mitochondrial distribution patterns that are indicative of
adult stem cells [80]. They appear to possess oval-like mitochondria [80] that have not formed the
complex networks associated with differentiated cells [18]. Indeed, these cell types primarily utilise
glycolysis to generate energy with little assistance from OXPHOS. The key factor associated with these
mitochondria would be their ability to increase in number as they differentiate towards a mature oocyte
that has fertilization capacity. This process would be mediated by nuclear-encoded factors associated
with mitochondrial biogenesis that would include the Sirtuin family members SIRT1 and 3; as well as
PGC1α, PPARγ, NRF1/2, and the estrogen-related receptor (ERR) α/β [81,82]. Likewise and, in terms of
mtDNA, they would need to increase copy number in the final stages of oocyte maturation, mediated
through the nuclear-encoded mtDNA replication factors that would include TFAM, mtSSB, Twinkle,
POLGA, POLGB, and TOP1MT [49,51]. Failure to do so would likely result in failure to develop to
the metaphase II-stage, fertilize, or develop through to the blastocyst stage. This would be a similar
outcome for women who exhibited developmental arrest resulting from too few mtDNA copies present
at the time fertilization [72–74,83], and similar to the mtDNA depletion syndromes associated with
mitochondrial disease in somatic tissues [84,85]. These diseases often arise from mutations present
in POLGA [86] and TFAM [87] and, consequently, result in the protein being poorly expressed and a
failure to faithfully replicate the mitochondrial genome.
In human and other mammalian oocytes, decreased expression of POLGA has resulted in the
failure of oocytes to fertilize [69,88]. This likely arises from levels of DNA methylation regulating the
expression of this gene [67] rather than due to mutation as is the case in mitochondrial disease [86].
However, supplementation of poor quality oocytes with extra naïve, oval mitochondria, containing
mtDNA, differentially methylated specific CpG sites within the large CpG island in POLGA between
the metaphase II oocyte and 2-cell embryo stages [69]; and resulted in improved fertilization and
blastocyst rates [36]. Consequently, if female germline stem cells are to be used as a source of oocytes
in assisted reproduction, it is essential that they adopt the characteristics of the differentiating oocyte
and regulate DNA methylation and mtDNA replication events in a synchronous manner to produce
viable oocytes.
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9. The Transmission of mtDNA Mutations and Variants through the Female Germline and
mtDNA Disease
It has been well-established that the female germline harbors variants and mutations that can
be transmitted through to the offspring (for an extensive review see [85]). Indeed, it has been argued
that the population of mtDNA within the female germline is a distinct, protected population of
mitochondrial genomes that do not harbor all of the variants that can be identified in the somatic
tissues [89–92]. This is likely due to the selection, or ‘mitochondrial bottleneck’, events that take place
very early during oogenesis to refine or select for specific variants or mutations that are transmitted
through the germline [93,94]. Indeed, somatic tissues can harbor spontaneous or de novo variants that
more frequently occur in the mitochondrial genome than in the nuclear genome [95] perhaps due to
the mode of packaging afforded to the mitochondrial genome [50,96]. Nevertheless, for the pathogenic
mtDNA mutations and deletions that give rise to the severe and, sometimes, fatal, multi-systemic
mitochondrial diseases, the levels of these rearrangements can be very different in the germline
compared to somatic tissues [89–92]. For example, oocytes can harbor high levels of pathogenic
rearrangements that, when prevalent in somatic tissues, can give rise to severe mitochondrial disease.
Indeed, 1:200 women are carriers of pathogenic rearrangements [89,97,98], however, the incidence of
mitochondrial disease is 1:5000 to 1:10,000 [85]. This clearly suggests that, post-gastrulation, there is
selection for and against these rearrangements. However, non-pathogenic rearrangements, which are
present in the germline and are found at high levels in mature oocytes, tend to be suppressed in somatic
tissues, which suggests a favorable selection of wild type molecules to support fetal development and
the well-being of the resultant offspring [99].
In order to maintain these important mitochondrial selection events in female germline stem
cells, especially those derived through stem cell technologies, it is essential that these cells harbor
rearrangements and variants similar to those present in primordial germ cells and the resultant mature
oocyte associated with that particular maternal lineage. Indeed, the use of mtDNA next generation
sequencing technology, as with its forerunners, has been extremely useful in identifying maternal
ancestral lineages; and can be applied to determine whether putative germline stem cells originate from
the pool of progenitor stem cells that give rise to the primordial germ cells. In a study using a mini-pig
model derived from a single maternal ancestor that had been characterized for mtDNA rearrangements
over several generations [99], egg precursor cells isolated from the ovaries of several females showed a
very close alignment to the rearrangements specific to the germline; hence supporting the hypothesis
that these cells were of germline origin [100]. The interesting concept to determine in this context
is whether the mtDNA profiles of those female germline stem cells derived from embryonic stem
cells or through somatic cell reprogramming revert to germline origin not just from a copy number
perspective but also through the rearrangements that they harbor. This would answer some key
questions: (1) Would the reprogrammed nucleus of the differentiated nucleus, if involved in the
selection of rearrangements, select in the same manner as primordial germ cells and potentially egg
precursor cells? (2) If not, would this have the propensity to purify or contaminate the female germline
with wanted/unwanted variants? (3) Would the rearrangements affect the gene expression profiles of
the germline stem cells as is the case for tumor-initiating cells when their mtDNA backgrounds are
altered [101]? and (4) the generation of female germline stem cells from human and mouse embryonic
stem cells would perhaps help answer the age-old question of whether the later stage characteristics of
human embryonic stem cells are really truly pluripotent and have the potential to give rise to germline
stem cells.
10. The Use of Female Germline Stem Cells to Overcome Female-Factor Infertility and
mtDNA Disease
The ability to isolate egg precursor cells [1,4,102] and to derive female germline stem cells from
embryonic [103,104] or induced pluripotent stem cells [105,106] offers considerable hope for infertile
couples whose infertility relates to oocyte quality. These cells can be either cultured in vitro to
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produce mature, metaphase II oocytes and fertilized to generate embryos for transfer to the mother;
or transplanted into the recipient’s ovary to promote ovarian function and to increase the likelihood
of achieving a pregnancy and a live birth, as so far demonstrated in mouse models [107,108]. They
could also be used as a source of mtDNA to promote fertilization outcome for couples who suffer
from mtDNA deficiency of the oocyte, namely where there are too few copies of mtDNA to support
fertilization outcome [34,36]. This form of autologous mitochondrial supplementation is designed to
overcome the ethical and health issues associated with cytoplasmic transfer, where cytoplasm from the
oocytes of a young donor has been introduced into the patient’s oocyte and resulted in heteroplasmic
offspring and severe associated disorders [109–111]. This approach has now been banned by many
countries that have embryo regulating authorities. However, in a pig model, the use of autologous
mitochondrial supplementation appears to improve embryo development rates and gene expression
profiles by the blastocyst stage when mitochondria were isolated from sister oocytes [36]. Nevertheless,
a recent study has demonstrated that autologous mitochondrial supplementation using egg precursor
cell mitochondria can result in the transgenerational transmission of a heart defect [112]. Whilst this
study was conducted in a mouse model, further investigation is required in a large animal model prior
to progressing clinical trials. That having been said, a few pregnancies and live births that have been
generated using this technology [113,114]. Nevertheless, the use of this technology in a clinical setting
should be halted until the procedure has been fully validated in a large animal model with a similar
embryo and pathophysiology to that of humans.
Studies in somatic cell cybrids have shown that a cell’s mtDNA can be replaced with another
population of mtDNA [115]. This has also been shown in embryonic stem cell models whereby the
chromosomal genome remained unchanged but each cell line possessed a different population of
mtDNA [116,117]. These models allow the influence of the mitochondrial genome to be investigated
under the same nuclear genome background and demonstrate how mtDNA haploytypes can influence
DNA methylation and nuclear gene expression patterns [116,117]. Consequently, an approach to
overcome the transmission of mutated or deleted mtDNA from the female carrier could be mediated
by replacing her mtDNA with that from a female non-carrier (Figure 3).
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Figure 3. The use of female germline stem cells to overcome mtDNA disease. Female germline stem 
cells from a carrier of a mtDNA mutation or deletion can be depleted of their mtDNA and fused to 
an enucleated stem cell harboring unaffected (non-mutated or deleted) mtDNA from a donor source 
to generate a reconstructed female ‘cybrid’ germline stem cell. The cell can then be proliferated and 
cultured to the metaphase II stage in readiness for fertilization. 
If this approach were to be performed in egg precursor or embryonic stem cells derived from 
the carrier, there would be the potential to generate embryos from mature female germline stem cells. 
Nevertheless, it is important to recognize that the selection of the most appropriate mtDNA 
haplotype is essential in order that the resultant cells function effectively and are able to undergo the 
Figure 3. The use of female germline stem cells to overcome mtDNA disease. Female germline stem
cells from a carrier of a mtDNA mutation or deletion can be depleted of their mtDNA and fused to
an enucleated stem cell harboring unaffected (non-mutated or deleted) mtDNA from a donor source
to generate a reconstructed female ‘cybrid’ germline stem cell. The cell can then be proliferated and
cultured to the metaphase II stage in readiness for fertilization.
If this approach were to be performed in egg precursor or embryonic stem cells derived from
the carrier, there would be the potential to generate embryos from mature female germline stem
cells. Nevertheless, it is impor ant to ecognize that the selection of the most approp ate mtDNA
haplotype is essential in order that the resultant cells function effectively and are able to undergo
the epigenetic and gene expression changes that take place during germ cell differentiation as well
as populating their cytoplasms with sufficient mitochondria and copies of mtDNA (see Figure 4).
Indeed, cell function is highly dependent on the compatibility of the nuclear and the mitochondrial
genomes with incompatibility, leading to cell dysfunction, poor nuclear gene expression profiles, and
perturbed DNA methylation profiles, as demonstrated in embryonic stem cells models of mtDNA
haplotypes [101,116,117]; and a model of germ cell differentiation, which resulted in ovarian failure
and embryonic lethality [118].
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Overall, there is much to discover regarding the role of mitochondria and mtDNA and its 
replication in female germline stem cells. However, from our knowledge of other closely related 
cellular systems, for example embryonic and adult stem cells, it is evident that they have significant 
roles to play. A key facet is the interaction between the nuclear and mitochondrial genomes to 
regulate mtDNA replication to ensure, during early development, mtDNA copy number is 
maintained at low levels to promote proliferation but, as differentiation takes place, the copy number 
needs to increase in an exponential manner (Figure 4). This will ensure that the mature oocyte can 
provide its mtDNA investment to support subsequent developmental events. Failure would result in 
failed fertilization or embryo arrest during preimplantation development. These processes are 
coupled with epigenetic changes and altered gene expression profiles during germ cell differentiation 
(Figure 4). These events will ultimately determine whether female germline stem cells isolated from 
the ovary or derived from embryonic stem cells or reprogrammed somatic cells have the potential to 
Figure 4. Germ cell differentiation. Stage-specific, synchronized interactions between the nuclear and
mitochondrial genomes during germ cell differentiation and oogenesis are required to establish a viable
and functional oocyte fit for fertilization (metaphase II oocyte).
This approach overcomes the nec ssity for o cyte manipul ti t e se of donor ocytes that
are currently required for the two techn logies associ ted with m ochondrial donation to produce
offspring that would, otherwise, be likely to inherit mitoch ndrial disease, na el s indle and
pronuclear transfer [119,120]. Indeed, the two technologies are also highly dependent on the most
appropriate mtDNA haplotype from an unaffected donor oocyte being selected [42]. Furthermore,
use of the cybrid approach would allow the interactions of the nuclear and mitochondrial genomes to
be established throughout germ cell differentiation, which might not be fully resolved when spindle
and pronuclear transfer are performed, given that these technologies are based on the products of
end-stage differentiation. However, we are a long way from being able to offer the manipulation of
female germline stem cells to treat mitochondrial disease.
11. Conclusions
Overall, there is much to discover regarding the role of mitochondria and mtDNA and its
replication in female germline stem cells. However, from our knowledge of other closely related
cellular systems, for example embryonic and adult stem cells, it is evident that they have significant
roles to play. A key facet is the interaction between the nuclear and mitochondrial genomes to regulate
mtDNA replication to ensure, during early development, mtDNA copy number is maintained at low
levels to promote proliferation but, as differentiation takes place, the copy number needs to increase in
an exponential man er (Figure 4). This will ensure that the mature oocyte can provide its mtDNA
investment to support subsequent developm tal ev nts. Failure would r sult in failed fertilization
or embryo arrest during preimplantation d velopment. Th se processes ar coupled with epigenetic
changes and altered gene expression profiles during germ cell differentiation (Figure 4). These events
will ultimately determine whether female germline stem cells isolated from the ovary or derived
from embryonic stem cells or reprogrammed somatic cells have the potential to generate healthy
and metabolically fit offspring and allow their genomes to be modified to prevent the transmission
of disease.
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